Edgewise Therapeutics (EWTX) Research & Development (2020 - 2026)

Edgewise Therapeutics (EWTX) has 7 years of Research & Development data on file, last reported at $42.7 million in Q1 2026.

• For the quarter ending Q1 2026, Research & Development rose 16.04% year-over-year to $42.7 million; the trailing twelve-month figure through Mar 2026 stood at $157.3 million (up 15.62% YoY), and the FY2025 full-year result was $151.4 million, up 19.24% from the prior year.
• Research & Development slipped to $42.7 million in Q1 2026, from $43.6 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $43.6 million in Q4 2025 to a low of $11.1 million in Q1 2022.
• A 5-year average of $27.4 million and a median of $27.7 million in 2024 frame the typical range for Research & Development.
• Across the five-year window, Research & Development surged 107.54% in 2022 and climbed 9.38% in 2025, its largest moves.
• Tracing EWTX's Research & Development over 5 years: stood at $16.6 million in 2022, then jumped by 66.65% to $27.7 million in 2023, then jumped by 31.38% to $36.4 million in 2024, then rose by 19.86% to $43.6 million in 2025, then dropped by 2.16% to $42.7 million in 2026.
• Business Quant data shows EWTX's Research & Development at $42.7 million in Q1 2026, $43.6 million in Q4 2025, and $37.5 million in Q3 2025.